Literature DB >> 9774598

Evaluation of the Nuclisens HIV-1 QT assay for quantitation of human immunodeficiency virus type 1 RNA levels in plasma.

M Segondy1, T D Ly, M Lapeyre, B Montes.   

Abstract

Nuclisens HIV-1 QT is a new version of the NASBA HIV-1 QT assay for quantitation of human immunodeficiency virus type 1 (HIV-1) RNA in plasma. The specificity of this assay was 100% in one laboratory and 99%-with nonrepeatability of the initial false positive-in another. The test was linear between 2.0 and 6.0 log RNA copies per ml. According to the input HIV-1 RNA concentration, accuracy varied from -0.11 to +0.10 log RNA copy per ml and precision varied from 0.66 to 0.14 log RNA copy per ml. Reproducibility decreased when the HIV-1 RNA level was near the lower limit of quantitation of the test. HIV-1 RNA could be quantitated by Nuclisens HIV-1 QT in 36% (laboratory 1) and 24% (laboratory 2) of clinical samples with HIV-1 RNA levels lower than the lower limit of quantitation by NASBA HIV-1 QT. Nuclisens HIV-1 QT was not suitable for measurement of RNA from clade G and group O HIV-1 strains.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9774598      PMCID: PMC105334     

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  11 in total

1.  Rapid and simple PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasma: application to acute retroviral infection.

Authors:  J Mulder; N McKinney; C Christopherson; J Sninsky; L Greenfield; S Kwok
Journal:  J Clin Microbiol       Date:  1994-02       Impact factor: 5.948

2.  An enhanced-sensitivity branched-DNA assay for quantification of human immunodeficiency virus type 1 RNA in plasma.

Authors:  D Kern; M Collins; T Fultz; J Detmer; S Hamren; J J Peterkin; P Sheridan; M Urdea; R White; T Yeghiazarian; J Todd
Journal:  J Clin Microbiol       Date:  1996-12       Impact factor: 5.948

3.  Multicenter comparison of three commercial methods for quantification of human immunodeficiency virus type 1 RNA in plasma.

Authors:  R Schuurman; D Descamps; G J Weverling; S Kaye; J Tijnagel; I Williams; R van Leeuwen; R Tedder; C A Boucher; F Brun-Vezinet; C Loveday
Journal:  J Clin Microbiol       Date:  1996-12       Impact factor: 5.948

4.  Comparative evaluation of three assays for the quantitation of human immunodeficiency virus type 1 RNA in plasma.

Authors:  J Coste; B Montes; J Reynes; M Peeters; C Segarra; J P Vendrell; E Delaporte; M Segondy
Journal:  J Med Virol       Date:  1996-12       Impact factor: 2.327

5.  The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team.

Authors:  D A Katzenstein; S M Hammer; M D Hughes; H Gundacker; J B Jackson; S Fiscus; S Rasheed; T Elbeik; R Reichman; A Japour; T C Merigan; M S Hirsch
Journal:  N Engl J Med       Date:  1996-10-10       Impact factor: 91.245

6.  Factors underlying spontaneous inactivation and susceptibility to neutralization of human immunodeficiency virus.

Authors:  S P Layne; M J Merges; M Dembo; J L Spouge; S R Conley; J P Moore; J L Raina; H Renz; H R Gelderblom; P L Nara
Journal:  Virology       Date:  1992-08       Impact factor: 3.616

7.  Quantification of HIV-1 RNA in plasma using NASBA during HIV-1 primary infection.

Authors:  B van Gemen; T Kievits; R Schukkink; D van Strijp; L T Malek; R Sooknanan; H G Huisman; P Lens
Journal:  J Virol Methods       Date:  1993-07       Impact factor: 2.014

8.  Association of plasma human immunodeficiency virus type 1 RNA level with risk of clinical progression in patients with advanced infection. AIDS Clinical Trials Group (ACTG) 116B/117 Study Team. ACTG Virology Committee Resistance and HIV-1 RNA Working Groups.

Authors:  R W Coombs; S L Welles; C Hooper; P S Reichelderfer; R T D'Aquila; A J Japour; V A Johnson; D R Kuritzkes; D D Richman; S Kwok; J Todd; J B Jackson; V DeGruttola; C S Crumpacker; J Kahn
Journal:  J Infect Dis       Date:  1996-10       Impact factor: 5.226

9.  Prognosis in HIV-1 infection predicted by the quantity of virus in plasma.

Authors:  J W Mellors; C R Rinaldo; P Gupta; R M White; J A Todd; L A Kingsley
Journal:  Science       Date:  1996-05-24       Impact factor: 47.728

10.  Evaluation of proviral copy number and plasma RNA level as early indicators of progression in HIV-1 infection: correlation with virological and immunological markers of disease.

Authors:  C Verhofstede; S Reniers; F Van Wanzeele; J Plum
Journal:  AIDS       Date:  1994-10       Impact factor: 4.177

View more
  11 in total

1.  Quantitation of human immunodeficiency virus type 1 group O load in plasma by measuring reverse transcriptase activity.

Authors:  J G García Lerma; V Soriano; A Mas; M E Quiñones-Mateu; E J Arts; W Heneine
Journal:  J Clin Microbiol       Date:  2000-01       Impact factor: 5.948

2.  Performance of NucliSens HIV-1 EasyQ Version 2.0 compared with six commercially available quantitative nucleic acid assays for detection of HIV-1 in China.

Authors:  Sihong Xu; Aijing Song; Jianhui Nie; Xiuhua Li; Youchun Wang
Journal:  Mol Diagn Ther       Date:  2010-10-01       Impact factor: 4.074

3.  Detection of HIV-1 minority variants containing the K103N drug-resistance mutation using a simple method to amplify RNA targets (SMART).

Authors:  Kenneth Morabito; Rami Kantor; Warren Tai; Leeann Schreier; Anubhav Tripathi
Journal:  J Mol Diagn       Date:  2013-03-29       Impact factor: 5.568

4.  Comparison of the LCx human immunodeficiency virus (HIV) RNA quantitative, RealTime HIV, and COBAS AmpliPrep-COBAS TaqMan assays for quantitation of HIV type 1 RNA in plasma.

Authors:  Vincent Foulongne; Brigitte Montes; Marie-Noelle Didelot-Rousseau; Michel Segondy
Journal:  J Clin Microbiol       Date:  2006-08       Impact factor: 5.948

5.  Comparison of human immunodeficiency virus type 1 RNA sequence heterogeneity in cerebrospinal fluid and plasma.

Authors:  Y W Tang; J T Huong; R M Lloyd; P Spearman; D W Haas
Journal:  J Clin Microbiol       Date:  2000-12       Impact factor: 5.948

6.  Impact of human immunodeficiency virus type 1 (HIV-1) genetic diversity on performance of four commercial viral load assays: LCx HIV RNA Quantitative, AMPLICOR HIV-1 MONITOR v1.5, VERSANT HIV-1 RNA 3.0, and NucliSens HIV-1 QT.

Authors:  Priscilla Swanson; Carmen de Mendoza; Yagnya Joshi; Alan Golden; Richard L Hodinka; Vincent Soriano; Sushil G Devare; John Hackett
Journal:  J Clin Microbiol       Date:  2005-08       Impact factor: 5.948

7.  Multicenter comparison of Roche COBAS AMPLICOR MONITOR version 1.5, Organon Teknika NucliSens QT with Extractor, and Bayer Quantiplex version 3.0 for quantification of human immunodeficiency virus type 1 RNA in plasma.

Authors:  D G Murphy; L Côté; M Fauvel; P René; J Vincelette
Journal:  J Clin Microbiol       Date:  2000-11       Impact factor: 5.948

8.  Evaluation of the abbott LCx HIV-1 RNA quantitative, a new assay for quantitative determination of human immunodeficiency virus type 1 RNA.

Authors:  N Zanchetta; G Nardi; L Tocalli; L Drago; C Bossi; F R Pulvirenti; C Galli; M R Gismondo
Journal:  J Clin Microbiol       Date:  2000-10       Impact factor: 5.948

9.  Single rapid real-time monitored isothermal RNA amplification assay for quantification of human immunodeficiency virus type 1 isolates from groups M, N, and O.

Authors:  M P de Baar; M W van Dooren; E de Rooij; M Bakker; B van Gemen; J Goudsmit; A de Ronde
Journal:  J Clin Microbiol       Date:  2001-04       Impact factor: 5.948

10.  Evaluation of the clinical sensitivities of three viral load assays with plasma samples from a pediatric population predominantly infected with human immunodeficiency virus type 1 subtype G and BG recombinant forms.

Authors:  Rute Antunes; Sofia Figueiredo; Inês Bártolo; Manuel Pinheiro; Lino Rosado; Isabel Soares; Helena Lourenço; Nuno Taveira
Journal:  J Clin Microbiol       Date:  2003-07       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.